Effect of a Unani Herbal Medicine Chilbeenj on Blood Sugar Control in Patients with Type 2 Diabetes.

Clinical Efficacy Of Chilbeenj (Strychnos Potatorum) In The Management Of Dhayabitus Sukkari (Type 2 Diabetes Mellitus): A Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099559

Enrollment

Registered

2025-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Chilbeenj/Nirmali (strychnos potatorum): Group A:powdered chilbeenj in capsules 500mg twice a day after food for 4 weeks Control Intervention1: Metformin 500mg: Group B: Tab: Metformin

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 30 years to 60 years 2. Both Genders 3. Recently Diagnosed Cases of Type 2 DM up to 3 years 4. Fasting Blood Sugar (FBS) Less than or equal to 126mg/dl Up to 200mg/dl 5.2hr Plasma Glucose (2PG) less than or equal to 200 mg/dl Up to 300 mg /dl 6.HbA1C more than 6.5 up to 9 7. Participants willing to participate in this study 8. Patients taking less than or equal to 2 hypoglycaemic drugs will be included in the study

Exclusion criteria

Exclusion criteria: 1. History of allergy or intolerance to any drug, 2. Type 1 diabetes, 3. Fasting blood sugar (FBS) more than 200mg/dl, 4. 2-hr Plasma Glucose (2PG) more than 300mg/dl, 5.HbA1C more than 10, 6. Diabetic patients with serious acute and chronic complications, such as diabetic ketoacidosis, Known cases of type 2 diabetes mellitus requiring insulin treatment 7. Pregnant or lactating women, 8. Patients who are on medication more than 3 hypoglycemic drugs, 9. History of Patients with known systemic illnesses such as chronic kidney disease, liver disorders, cardiovascular disease, or autoimmune conditions will be excluded. 10. Alcoholics, smokers, and drug addicts.

Design outcomes

Primary

Measure	Time frame
Reduction in FBS and 2-hr PPBSTimepoint: 4 weeks : 0 (baseline), 2 weeks, 4 weeks	—

Secondary

Measure	Time frame
1. changes in oxidative stress markers PC Protein Carbonyl(27), FRAP Ferric Reducing Antioxidant Power(28). 2. Improvement in ADQOL (Asian Diabetes Quality of Life) 3. HbA1c level Timepoint: 0 (baseline), and 4 weeks	—

Countries

India

Contacts

Public ContactDr MUBASHEERA BEGUM

Government Unani Medical College

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026